Stroke-like leukopathy in children with acute lymphoblastic leukemia
https://doi.org/10.21682/2311-1267-2021-8-1-14-22
Abstract
There are considerable variations in the reported incidence methotrexate-induced neurotoxicity in children with malignancies. The etiology of acute neurological deficit in pediatric patients with malignancies during polychemotherapy can be diverse: cerebrovascular disease (arterial ischemic stroke, intracranial hemorrhage, venous sinus thrombosis, or their combination), stroke-like migraine attacks after radiation therapy (SMART), posterior reversible encephalopathy syndrome (PRES), thrombotic microangiopathy, toxic leukoencephalopathy (include strokelike leukoencephalopathy). The tactics of a neurologist largely depends on the reasons that caused the neurological deficit. The doctor needs knowledge not only of the clinical picture and the characteristics of the course of the underlying disease, but also of possible complications arising both as a result of the disease itself and due to the therapy being carried out. Timely diagnosis and correct interpretation of emerging neurological events make it possible to determine rational accompanying therapy. The article presents case histories of children with acute lymphoblastic leukemias and acute neurological deficits, with an analysis of their possible causes.
About the Authors
N. V. Natrusova
Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow;
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Neurologist Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow, Neurologist,
1/9 4th Dobryninskiy Per., Moscow, 119049;
23 Kashirskoe Shosse, Moscow, 115478
I. O. Shchederkina
Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Neurologist, Head of the Center for the Treatment of Cerebrovascular Diseases in Children and Adolescents,
1/9 4th Dobryninskiy Per., Moscow, 119049
E. V. Seliverstova
Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Radiologist,
1/9 4th Dobryninskiy Per., Moscow, 119049
O. A. Tiganova
Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow
1/9 4th Dobryninskiy Per., Moscow, 119049
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Chief External Oncologist at the Department of Health in Moscow, Hematologist-oncologist, 1/9 4th Dobryninskiy Per., Moscow, 119049;
Associate Professor Department of Pediatrics, 1 Ostrovityanova St., Moscow, 117997
K. L. Kondratchik
Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Head of the Center for Pediatric Oncology and Hematology, Head of the Department of Oncology and Hematology, 1/9 4th Dobryninskiy Per., Moscow, 119049;
Associate Professor Department of Oncology, Hematology and Immunology, 1 Ostrovityanova St., Moscow, 117997
References
1. Inaba H., Pui C.H. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev 2019;38(4):595–610. doi: 10.1007/s10555-019-09834-0.
2. Navarrete-Meneses M.D.P., Pérez-Vera P. Alteraciones epigenéticas en leucemia linfoblástica aguda [Epigenetic alterations in acute lymphoblastic leukemia]. Bol Med Hosp Infant Mex 2017;74(4):243–64. doi: 10.1016/j.bmhimx.2017.02.005.
3. Ayalon I., Friedman S., Binenbaum Y., Oppenheimer N., Shiran S., Grisaru-Soen G., Uliel-Sibony S., Glatstein M., Kaplan J.M., Sadot E. A Case of Methotrexate Neurotoxicity Presented as Status Epilepticus, Encephalopathy, and High Fever. J Investig Med High Impact Case Rep 2019;7:2324709619862311. doi: 10.1177/2324709619862311.
4. Vezmar S., Becker A., Bode U., Jaehde U. Biochemical and Clinical Aspects of Methotrexate Neurotoxicity. Chemotherapy 2003;49:92–104. doi: 10.1159/000069773.
5. Bhojwani D., Sabin N.D., Pei D., Yang J.J., Khan R.B., Panetta J.C., Krull K.R., Inaba H., Rubnitz J.E., Metzger M.L., Howard S.C., Ribeiro R.C., Cheng C., Reddick W.E., Jeha S., Sandlund J.T., Evans W.E., Pui C.H., Relling M.V. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014;32(9):949–59. doi: 10.1200/JCO.2013.53.0808.
6. Forster V.J., van Delft F.W., Baird S.F., Mair S., Skinner R., Halsey Ch. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol 2016;78:1093–6. doi: 10.1007/s00280-016-3153-0.
7. Pape L., Hartmann H., Bange F.C., Suerbaum S., Bueltmann E., Ahlenstiel-Grunow T. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015;94(24):e1000. doi: 10.1097/MD.0000000000001000. 8. Singh A.K., Tantiwongkosi B., Moise A.M., Altmeyer W.B. Stroke-like migraine attacks after radiation therapy syndrome: Case report and review of the literature. Neuroradiol J 2017;30(6):568–73. doi: 10.1177/1971400917690009.
8. Flott-Rahmel B., Schürmann M., Schluff P., Fingerhut R., Musshoff U., Fowler B., Ullrich K. Homocysteic and homocysteine sulphinic acid exhibit excitotoxicity in organotypic cultures from rat brain. Eur J Pediatr 1998;157 Suppl 2:S112–7. doi: 10.1007/pl00014291.
9. Pope S., Artuch R., Heales S., Rahman S. Cerebral folate defi ciency: Analytical tests and diff erential diagnosis. J Inherit Metab Dis 2019;42(4):655–72. doi: 10.1002/jimd.12092.
10. Campbell J.M., Bateman E., Stephenson M.D., Bowen J.M., Keefe D.M., Peters M.D. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol 2016;78(1):27–39. doi: 10.1007/s00280-016-3043-5.
11. Rubinstein L.J., Herman M.M., Long T.F., Wilbur J.R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975;35(2):291–305. doi: 10.1002/1097-0142(197502)35:23.0.co;2-v.
12. Cheung Y.T., Sabin N.D., Reddick W.E., Bhojwani D., Liu W., Brinkman T.M., Glass J.O., Hwang S.N., Srivastava D., Pui C.H., Robison L.L., Hudson M.M., Krull K.R. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. Lancet Haematol 2016;3(10):e456–66. doi: 10.1016/S2352-3026(16)30110-7.
Review
For citations:
Natrusova N.V., Shchederkina I.O., Seliverstova E.V., Tiganova O.A., Kondratchik K.L. Stroke-like leukopathy in children with acute lymphoblastic leukemia. Russian Journal of Pediatric Hematology and Oncology. 2021;8(1):14-22. (In Russ.) https://doi.org/10.21682/2311-1267-2021-8-1-14-22
Views:
2024
Email this article 